Nurse Practitioners, Physician Assistants Clash With Physicians in #StopScopeCreep Movement
The AMA chose to delete its #StopScopeCreep post after receiving criticism from advanced practice providers.
Facebook CMO Antonio Lucio steps down
He cites ‘challenging year’ and desire to focus full time on diversity and inclusion.
Facebook removed 7m COVID-19 misinformation posts in three months
Social network has shed light on scale of coronavirus misinformation problem.
Five things for pharma marketers to know: Wednesday, July 29, 2020
Advocates call on Facebook to control vaccine misinformation; Democratic lawmakers to investigate government’s role in developing remdesivir; Pfizer CEO criticizes Trump drug price orders.
Novartis, Pfizer among drug makers giving thumbs-up to Facebook ad boycott
A number of pharma companies are pausing ads on the social network this month, either in solidarity with #StopHateForProfit’s July boycott or due to brand safety concerns.
Facebook, medical associations launch preventive health tool
The social giant says information collected will be stored securely, with controls on advertising.
Why pharma should start paying more attention to Instagram
Facebook Health’s Danielle Salowski and Merck’s Nancy Nolan shared best practices for Instagram at Digital Pharma East in Philadelphia.
The status of online health communities post-Cambridge Analytica
For many online health communities, the Facebook-Cambridge Analytica scandal didn’t have a significant impact, and members still see the social network as an invaluable resource.
Twitter follows Facebook in share price plunge as monthly active users fall
Despite some other positive indicators, Twitter’s share price fell 14% as the platform revealed a dip in its monthly active users in its second quarter results, compared to the previous quarter.
Facebook shares plunge amid first decline in European daily active users
Facebook sought to blame GDPR as it revealed its daily active users in Europe declined for the first time in nine years and it disappointed investors with lower-than-expected growth.
